Feasibility of a Modular mHealth for Tailored Rehabilitation of Breast Cancer (MMHTR)

October 25, 2022 updated by: JiHye Hwang, Samsung Medical Center

Feasibility of a Modular mHealth for Tailored Rehabilitation During the Treatment of Breast Cancer

This study investigated the feasibility of the novel modular mobile health (mHealth) for personalized rehabilitation and explored the participants' satisfaction and app data during treatment of breast cancer.

Study Overview

Status

Completed

Conditions

Detailed Description

This is prospective, feasible, parallel study in post-operative patients with breast cancer and during treatment. Disability of Arm, Shoulder, Hands (DASH), Physical activity data (IPAQ-SF), Physical measurement such as hand grip strength, body mass index (BMI), muscle mass, and differences in arm circumference, PRO-CTCAE, Distress Thermometer, needs and satisfaction in app, personal health record of app (exercise, daily step count, etc.) Measure will be evaluated on 1-month, 2-month, 4-month, 6-month, 9-month, and 12-month after POD.

Study Type

Interventional

Enrollment (Actual)

44

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Gangnam-gu
      • Seoul, Gangnam-gu, Korea, Republic of, 06351
        • Samsung Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 70 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Unilateral breast cancer at TNM stage 0 ~ III
  • Patients who will undergo the treatment (chemotherapy, radiation therapy, and hormone therapy) after surgery
  • Patients who had a mobile phone (Android or iOS)

Exclusion Criteria:

- Patients who have metastases or recurrence to other organs were excluded

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: SUPPORTIVE_CARE
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Self-management using mHealth
Self-management (physical activity, sleep, exercise, education, etc.) using mHealth
an individually tailored self-management through the mHealth app with a smart band worn on the wrist
Other Names:
  • mHealth
NO_INTERVENTION: Exercise using brochure
Only exercise using brochure

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
satisfaction score in app contents
Time Frame: 1 to 12month
satisfaction score in app contents, Likert scale (5-point, higher scores mean a better)
1 to 12month
Needs score in app contents
Time Frame: 1 to 12month
Needs score in app contents, Likert scale (5-point, higher scores mean a better)
1 to 12month
DASH (Disabilities of Arm, Shoulder, Hands)
Time Frame: 1 month, 2month, 4month, 6month, 9month, 12month
Change from Baseline DASH score at 12 months, higher scores mean a worse (0-100)
1 month, 2month, 4month, 6month, 9month, 12month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Physical measurement (handgrip strength)
Time Frame: 1 to 12month
Handgrip strength (kg)
1 to 12month
Physical measurement (of body composition, BMI)
Time Frame: 1 to 12month
Body mass index
1 to 12month
Physical measurement (of body composition, muscle mass)
Time Frame: 1 to 12month
muscle mass
1 to 12month
Physical measurement (upper extremity volume)
Time Frame: 1 to 12month
differences in arm circumference
1 to 12month
Physical activity (IPAQ-SF Questionnaire)
Time Frame: 1 to 12month
Total METs within recent 7 days (vigorous, moderate, walking, sitting), higher values mean a better
1 to 12month
PRO-CTCAE (patients reported outcomes)
Time Frame: 1 to 12month
Symptoms during treatment
1 to 12month
Distress thermometer (distress level)
Time Frame: 1 to 12month
Distress level during treatment, higher scores mean a worse (0-10)
1 to 12month
App use data (personal health record)_Exercise compliance rate
Time Frame: 1 to 12month
Exercise time, higher values mean a better
1 to 12month
App use data (personal health record)_Physical activity change
Time Frame: 1 to 12month
daily step count (number), higher values mean a better physical activity
1 to 12month
App use data (personal health record)_interest of contents
Time Frame: 1 to 12month
contents view (number), higher values mean a better compliance rate
1 to 12month
App use data (personal health record)_sleep
Time Frame: 1 to 12month
sleep compliance rate (%), higher values mean a better compliance rate
1 to 12month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

April 22, 2019

Primary Completion (ACTUAL)

March 30, 2021

Study Completion (ACTUAL)

March 30, 2021

Study Registration Dates

First Submitted

February 22, 2021

First Submitted That Met QC Criteria

March 1, 2021

First Posted (ACTUAL)

March 4, 2021

Study Record Updates

Last Update Posted (ACTUAL)

October 26, 2022

Last Update Submitted That Met QC Criteria

October 25, 2022

Last Verified

October 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • SMC-2018-10-062

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Clinical Trials on Modular mHealth for Tailored Rehabilitation

Subscribe